Use of Tregs as a cell‐based therapy via CD39 for benign prostate hyperplasia with inflammation

Journal of Cellular and Molecular Medicine

Xiaoting Chen¹  Guang Yang¹  Xinyang Liao²  Hongwen Ma²  Tianhai Lin²  Qiang Wei²  Lu Yang²  Kunjie Wang²  Hong Li²  Bo Tang²  Xi Jin²  Jianzhong Ai²  Hang Xu²  Ping Tan²  Jianqiong Yin²  Lina Gong²  Yi Sun²  Huawei Cai³  Huifang Li⁴ 

[1]Animal Experimental Center, West China Hospital, Sichuan University, Chengdu, China

[2]Department of Urology, Institute of Urology, West China Hospital, Sichuan University, Chengdu, China

[3]Laboratory of Clinical Nuclear Medicine, Department of Nuclear Medicine, West China Hospital, Sichuan University, Chengdu, China

[4]Research Core Facility, West China Hospital, Sichuan University, Chengdu, China

关键词: benign prostate hyperplasia;    CD39;    immunotherapy;    regulatory T cells;    transfusion;   

DOI  :  10.1111/jcmm.15137

来源: Wiley

【 授权许可】

CC BY